| |
|
|
|
|
|
|
|||
|
Blood, 1 March 2007, Vol. 109, No. 5, pp. 2234-2242. Prepublished online as a Blood First Edition Paper on November 2, 2006; DOI 10.1182/blood-2006-07-037473.
TRANSPLANTATION A GMCSF and IL-15 fusokine leads to paradoxical immunosuppression in vivo via asymmetrical JAK/STAT signaling through the IL-15 receptor complex1 The Montreal Centre for Experimental Therapeutics in Cancer, Jewish General Hospital, McGill University, Montreal, QC, 2 Molecular Oncology Laboratory, McGill University, Montreal, QC; 3 Department of Chemistry, University of Quebec at Montreal (UQAM), Montreal, QC; and 4 Division of Hematology/Oncology, Jewish General Hospital, McGill University, Montreal, QC
We hypothesized that a granulocyte macrophage colony-stimulating factor (GMCSF) and interleukin 15 (IL-15) fusokine (GIFT15) would possess greater immune-stimulatory properties than their combined use. Unexpectedly, tumor cells engineered to secrete GIFT15 protein led to suppression of natural killer (NK) and NKT-cell recruitment in vivo, suggesting an unanticipated immune-suppressive effect. We found GIFT15 to have pleiotropic effects on an array of immune-competent cells. Among these, macrophages treated with GIFT15 secrete de novo the tissue inhibitor of metalloproteinase-2 (TIMP-2); activated matrix metalloproteinase-2 (MMP-2); transforming growth factor-ß (TGF-ß); as well as vascular endothelial growth factor (VEGF). We show that the GIFT15 fusokine has increased affinity for the
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2007 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||